Autotelic Bio presents new TGF-β receptor type-1 inhibitors for cancer
Oct. 18, 2023
Autotelic Bio Inc. has divulged thiazole derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of cancer.